DOSIsoft has created DOSIsoft Theranostics as a dedicated business focused on software for personalized nuclear medicine and theranostics workflows. The company announced the new entity ahead of the SNMMI 2026 annual meeting in Los Angeles.
The unit will operate within the DOSIsoft group while pursuing its own partnerships, innovation agenda, and investment strategy, according to the announcement. DOSIsoft said the structure is intended to support broader routine clinical use of theranostics software.
PLANET is the product anchor for the new entity. The platform includes voxel-based multiradionuclide dosimetry capabilities and multimodality DICOM interoperability, according to DOSIsoft.
FDA documentation for PLANET Onco Dose 3.2 describes the software as a standalone system for managing, processing, displaying, and analyzing anatomical and functional images. The cleared indications include tools for diagnosis aid, contouring, therapy response assessment, and internal dosimetry computation for radionuclide-based therapies.
The FDA filing also states that PLANET Onco Dose is intended for retrospective dose determination and should not be used to deviate from approved radioactive product dosing and administration instructions. Supported modalities include CT, MRI, SPECT, PET, XA, planar scintigraphy, RT Struct, and RT Dose in DICOM format.
DOSIsoft said the theranostics entity will be present at SNMMI 2026 at booth #1358. The company said its broader installed base includes more than 1,000 installations across 800+ hospital centers in 80 countries.
Company:DOSIsoft
Sources
- 510(k) Summary K241765, PLANET Onco Dose 3.2. Regulatory filing
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
